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Background: There is concern about public understanding of overdiagnosis in breast cancer screening, and uncertainty about the
likely impact on screening participation.
Methods: In a population-based survey of 2272 women, we assessed understanding of overdiagnosis and screening intentions
before and after exposure to an explanation of overdiagnosis, and one of the three information formats providing an estimate of
the rate of overdiagnosis based on the findings of the UK Independent Review.
Results: Subjective and objective comprehension of overdiagnosis was moderate across information formats (64% and 57%,
respectively). Following overdiagnosis information, 7% of women showed a decrease in screening intention, with a stronger effect
among women below screening age (o47 years), and receiving the estimate of the rate of overdiagnosis in a simple ratio format
(one life saved to three overdiagnoses).
Conclusions: Brief written information on overdiagnosis was incompletely understood, but reduced breast screening intentions in
a proportion of women, regardless of comprehension. Subjective comprehension was lower among women who had not yet
reached screening age but the deterrent effect was higher.
Opinions on the efficacy of mammography screening for breast
cancer are divided in the scientific community (Duffy et al, 2010;
Gotzsche and Jorgensen, 2011). The lack of consensus among
experts, together with intrinsic difficulties in accurately estimating
rates of overdiagnosis, makes communicating with the public about
the harms and benefits of breast screening challenging. A recent
independent review in the UK concluded that mammography
screening is effective, but estimated that, for every life saved by the
NHS breast screening programme, approximately three women are
diagnosed and treated for a cancer that never would have harmed
them (Independent UK Panel on Breast Screening, 2012), though
this estimate is far from certain. The review recommended that the
NHS information materials should include clear information on
overdiagnosis, and they now include this information in three
formats (NHS, 2013).
Despite a rigorous development process (Hawkes, 2012;
Informed Choice about Cancer Screening, 2014), little is known
about the public’s understanding of overdiagnosis or the likely
impact of overdiagnosis information on women’s choices about
screening participation. Recent qualitative studies found that
information on overdiagnosis was difficult for screening-eligible
women to understand and was often surprising (Hersch et al, 2013;
Waller et al, 2013), but did not appear to have much impact on
screening intentions.
The first aim of this study was to assess change in screening
intention in response to overdiagnosis information, and to
test the hypothesis that intentions would be reduced more
among women who had not yet been invited for screening
than those already eligible, whose attitudes may be resistant
to change.
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The second aim was to compare the three formats of
overdiagnosis information included in the NHS information
materials. We hypothesised that the simple ratio format (lives
saved: overdiagnoses) would be easier to understand – and
therefore have more impact on screening intentions – than
information involving actual (large) numbers of lives saved or
women overdiagnosed (Trevena et al, 2013).
We addressed these aims using an experimental design in a
large, population-based sample. Participants were randomised to
one of the three formats of overdiagnosis information that are in
the current NHS leaflet. Comprehension was assessed after
exposure. Intention to attend was assessed before and after
information exposure. Given the particular interest in the extent
to which overdiagnosis information would reduce screening
participation, our main outcome of interest was decreased intention.
MATERIALS AND METHODS
The survey was carried out as part of TNS-International’s omnibus
survey in July 2013 using stratified random location sampling and
home-based computer-assisted personal interviewing. Data were
analysed from 2272 women aged 25–46 (below screening age) and
53–70 years (screening eligible), in England, Scotland or Wales (see
‘Supplementary File 1’ for details of participant flow).
The main outcome measure was intention to participate in
future breast screening (see ‘Supplementary File 2’ for details of
measures and coding). This was asked before and after exposure to
overdiagnosis information. Change in intention was coded as
‘decrease’ vs ‘no decrease’.
Before information exposure, we assessed previous awareness of
overdiagnosis. Subjective comprehension of the overdiagnosis
information was assessed using items adapted from Woloshin
et al (2005), and objective comprehension by asking whether
attending screening increased or decreased the likelihood of a
breast cancer diagnosis (Hersch et al, 2013). Previous breast
screening participation, age, marital status and socioeconomic
status (based on the sum of responses to questions on occupational
group, education, and car ownership) were also assessed.
Participants received a brief explanation of the concept of
overdiagnosis (for details, see ‘Supplementary File 3’) and were
randomised to one of three information conditions: Version 1 in
which the rate of overdiagnosis was framed as a ratio (one life
saved to three overdiagnoses), Version 2, which gave the total
number of overdiagnoses compared with lives saved in the UK
(4000 and 1300, respectively), or Version 3, which gave the
numbers of overdiagnoses and lives saved for every 200 women
screened for 20 years (3 and 1). All information was taken from the
new breast screening leaflet.
Analyses were carried out using PASW Statistics 20 (IBM Corp,
2011).
RESULTS
Baseline measures. Characteristics of the sample (n¼ 2272)
divided into the age-eligible range for screening (n¼ 954) and
not yet eligible for screening (n¼ 1318) are shown in Table 1. At
baseline, screening intention was high (91%, 2059/2272, expressed
a positive intention), and slightly higher in the age-eligible group.
Table 1. Baseline characteristics of the sample by screening eligibility (n and column %)
Not yet eligible for
screening (n¼1318)
Eligible for screening
(n¼954) P for difference
Age in years (mean; standard deviation; range) 35.3 (6.3) 25–46 62.1 (5.2) 53–70 NA
Marital status
Married/living as married 848 (64.3) 585 (61.3) w2(2)¼ 239.2,
Single 352 (26.7) 80 (8.4) Po0.0001
Separated/divorced/widowed 118 (9.0) 289 (30.3)
Socioeconomic statusa
0 (most deprived) 220 (16.9) 145 (15.6) w2(3)¼ 14.7,
1 432 (33.3) 359 (38.6) P¼ 0.002
2 379 (29.2) 287 (30.8)
3 (most affluent) 268 (20.6) 140 (15.0)
Breast screening history
Never screened NA 82 (8.7) NA
6 or more years ago 41 (4.4)
3–5 years ago 155 (16.5)
Less than 3 years ago 662 (70.4)
Breast screening intention (pre-information)
Probably/definitely yes 1187 (90.1) 872 (91.4) w2(2)¼ 19.2,
Not sure 78 (5.9) 24 (2.5) Po0.0001
Probably/definitely not 53 (4.0) 58 (6.1)
Previous awareness of overdiagnosis
Aware 592 (44.9) 608 (63.7) w2(1)¼ 78.6,
Unaware/don’t know 726 (55.1) 346 (36.3) Po0.0001
Sample sizes vary slightly owing to missing data
aComposite measure of socioeconomic status gives one point each for having degree-level qualifications, having a car in the household and being in occupational social grade A/B/C1.
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Around half were already aware of overdiagnosis (53%, 1200/
2272); slightly more in the age-eligible group.
Post-information measures. Subjective comprehension of over-
diagnosis information was expressed by about two-thirds of
women, with 64% showing no uncertainty on any of the subjective
measures (Table 2). Objective understanding was slightly lower,
with 57% correct. Younger women’s objective understanding was
better than older women’s (60% vs 53% correct, respectively), but
they were less subjectively certain (62% vs 68%, respectively).
Subjective and objective comprehension were modestly correlated
in the whole group (r¼ 0.14, P¼ 0.01) and both age groups
(younger: r¼ 0.14, P¼ 0.01; older: r¼ 0.16 P¼ 0.01). There were
no differences in objective or subjective comprehension by version
(see Table 2).
Screening intentions remained high after information exposure;
90% of respondents said they would ‘probably’ or ‘definitely’ attend
(Table 2). Among the 2262 respondents who answered the
intention question at both time points, 89% had no change in
intention, 4% increased their intention and 7% decreased their
intention. As hypothesised, younger women were more likely than
older women to show decreased intentions to participate (8% vs
5%, respectively; Table 2).
Consistent with our second hypothesis, significantly more
respondents exposed to Version 1 (ratio information) decreased
their intention (9%), compared with Version 2 (5%) or Version 3
(6%) (Table 2).
We used logistic regression analyses to examine predictors of
decreased screening intention (Table 3) controlling for marital
status and socioeconomic status. Decreased intention was more
likely in respondents not yet eligible for screening (OR¼ 1.96; 95%
CI: 1.33–2.89), exposed to Version 1 vs the other formats
(OR¼ 1.50; 95% CI: 1.02–2.22), with no prior awareness of
overdiagnosis (OR¼ 1.48; 95% CI: 1.05–2.08), and who expressed
subjective uncertainty about comprehension (OR¼ 1.47; 95% CI:
1.04–2.06). To test whether prior awareness or comprehension
mediated the age or version effects, we used a multivariate model.
Screening eligibility, version and subjective uncertainty remained
significantly associated with decreased intention, with little change
in the odds ratios. Previous awareness of overdiagnosis became
non-significant, indicating it was likely to be a marker of screening
eligibility.
DISCUSSION
In this population-based sample of women, prior awareness of
overdiagnosis in breast screening was moderate (53%), and
significantly lower (45%) in women not yet age-eligible for the
national breast screening programme. After exposure to any of the
three formats of overdiagnosis information used in the NHS
information leaflet, just over a third of women (36%) expressed
some uncertainty about their ability to interpret the information,
and almost half (43%) failed to understand that screening increases
Table 2. Differences in follow-up measures by screening eligibility and information version (n and column %)
Differences by screening eligibility Differences by information version
Whole
sample
(n¼2272)
Not yet
eligible
(n¼1318)
Screening
eligible
(n¼954) Difference
Version 1
(3 : 1
ratio)
(n¼758)
Version 2
(total
numbers)
(n¼736)
Version 3
(per 200
women)
(n¼778) Difference
Breast screening intention (post-info)
Probably/definitely yes 2041 (90.2) 1169 (89.0) 872 (92.0) v2(2)¼28.8, 683 (90.5) 669 (91.4) 689 (88.9) w2(4)¼3.7,
Not sure 118 (5.2) 95 (7.2) 23 (2.4) Po0.0001 37 (4.9) 37 (5.1) 44 (5.7) P¼0.45
Probably/definitely not 103 (4.6) 50 (3.8) 53 (5.6) 35 (4.6) 26 (3.6) 42 (5.4)
Missing 10
Change in intention (pre- to post-info)
No change/Increase in
intention
2112 (93.4) 1207 (91.9) 905 (95.5) v2(1)¼11.6, 689 (91.3) 695 (94.9) 728 (93.9) v2(2)¼8.8,
Decrease in intention 150 (6.6) 107 (8.1) 43 (4.5) P¼0.001 66 (8.7) 37 (5.1) 47 (6.1) P¼0.01
Missing 10
Objective understanding of overdiagnosisa
Correct 1283 (56.7) 784 (59.7) 499 (52.5) v2(1)¼11.8, 436 (57.8) 411 (55.9) 436 (56.3) w2(2)¼0.6,
Incorrect/don’t know 981 (43.3) 529 (40.3) 452 (47.5) P¼0.001 318 (42.2) 324 (44.1) 339 (43.7) P¼0.73
Missing 8
Subjective understanding of overdiagnosisb
Any uncertainty 802 (35.6) 497 (38.0) 305 (32.4) v2(1)¼7.5, 256 (34.3) 266 (36.2) 280 (36.3) w2(2)¼0.8,
No uncertainty 1449 (64.4) 812 (62.0) 637 (67.6) P¼0.006 490 (65.7) 468 (63.8) 491 (63.7) P¼0.66
Missing 21
Significant group differences are shown in bold Samples sizes vary slightly between analyses due to missing data.
aResponse to the question: who do you think is more likely to be diagnosed with breast cancer? Women who have screening mammograms (correct) or women who do not have screening
mammograms (incorrect).
bDerived from three items assessing ease of understanding, confidence in having made sense of the information and knowing how to interpret the information; see Supplementary File 2 for
wording and coding details.
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the risk of a breast cancer diagnosis; poorer understanding of
overdiagnosis than has been found following more detailed
explanations (Hersch et al, 2013). This suggests that, even leaving
aside the fact that that rate of overdiagnosis is a highly contested
issue, the concept itself is difficult to understand. Brief information,
of the sort sent to women in the UK with their screening
appointment, may not be enough to facilitate informed choice.
Although intentions to attend screening remained high after
overdiagnosis information, 5% of age-eligible women showed
decreased intentions to participate in screening; rising to 8%
among women not yet eligible for screening. This provides support
for our hypothesis that overdiagnosis information would have
more impact on women for whom a screening decision was novel,
whereas those already in the screening programme may have stable
beliefs and intentions.
We found small differences in intention change between
different versions of the numerical information. Expressing the
information as a ratio of lives saved to overdiagnoses (1 : 3) was
associated with a greater decrease in intention than the other
information formats. This suggested a better understanding of
information presented using small numbers, but in the analyses,
the effect of version was not explained by comprehension. The
perceived likelihood of overdiagnosis rather than the phenomenon
itself maybe more off-putting in the ratio format.
One limitation of the study is that women were provided with
little time to process the information, and thus our findings
demonstrate only its immediate impact. The outcome was
intention rather than actual screening uptake, which was
inevitable as we were interested in women outside the eligible
age range, but future research should assess the impact on actual
screening uptake. We did not have information on survey non-
responders so cannot rule out the possibility that our sample
differed systematically from the wider population, although by
using an omnibus survey, we minimised the chance that
participation would be biased by health-related beliefs. Finally,
we used the term ‘overdiagnosis’ rather than ‘overtreatment’,
which has been found to be preferred by some women (Hersch
et al, 2013) and provided only brief information that did not give
a nuanced account of the range of outcomes that might be
experienced following overdiagnosis. This may have had an
impact on our findings.
This study suggests that brief, written information on over-
diagnosis is unlikely to have a major impact on participation in
breast screening, but may be off-putting to women not yet eligible
for screening, particularly when they see the 1 : 3 ratio of lives saved
to overdiagnoses. If 8% of women invited for screening for the first
time decided not to attend, this would represent a significant drop
in screening coverage in the long term. More research is needed to
explore the impact of presenting women with personalised
information or with a range of estimates of the harms and benefits
of screening, as has been described in a recent US paper (Welch
and Passow, 2014). It will also be important to see whether
international differences in attitudes exist; and whether attitudes
change over time, as women are exposed to more information
about the limitations of screening.
Women in the general population in Britain appear to be less
concerned by the prospect of overdiagnosis than some clinicians;
although the simplest information format resulted in a small
reduction in intentions to participate, especially among women
who had not yet reached screening age. The relatively poor
comprehension combined with little impact on intentions suggests
that brief written materials may not achieve a full appreciation of
the balance of harms and benefits of breast screening, or counteract
the public’s very positive attitudes towards cancer screening in
general (Schwartz et al, 2004). However, the limited impact on
intentions could also be interpreted in the context of the ‘better
safe than sorry’ philosophy that has been observed in qualitative
research.
Table 3. Odds of decreased screening intention
n (row %) decreasing
intention
Adjusted odds ratiosa
(CI: 95%)
n¼2213–2223
Fully adjusted modelb
Odds ratio (CI: 95%)
n¼2207
Screening eligibility group
Screening eligible (ref) 43 (4.5) 1.00 1.00
Not yet eligible 107 (8.1) 1.96 (1.33–2.89) 1.84 (1.24–2.74)
Information version
Version 3 (per 200 women) (ref) 47 (6.1) 1.00 1.00
Version 1 (3 : 1 ratio) 66 (8.7) 1.50 (1.02–2.22) 1.62 (1.09–2.40)
Version 2 (total numbers) 37 (5.1) 0.81 (0.52–1.26) 0.83 (0.53–1.30)
Previous awareness of OD
Aware 66 (5.5) 1.00 1.00
Unaware/don’t know 84 (7.9) 1.48 (1.05–2.08) 1.31 (0.92–1.86)
Objective understanding of OD
Correct (ref) 86 (6.7) 1.00 1.00
Incorrect/don’t know 63 (6.5) 0.94 (0.66–1.32) 0.93 (0.65–1.32)
Subjective understanding of overdiagnosis information
No uncertainty (ref) 83 (5.7) 1.00 1.00
Any uncertainty 66 (8.3) 1.47 (1.04–2.06) 1.43 (1.01–2.02)
Abbreviation:OD¼overdiagnosis.
aOdds ratios are adjusted for marital status and SES. Sample sizes vary owing to missing data.
bModel includes all the variables in the table and adjusts for marital status and SES.
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